Dr. Lyon on a phase 2 study of in-home treatment for NMIBC
“The primary outcome will be feasibility of in-home treatments,” says Timothy D. Lyon, MD, FACS.
In this video, Timothy D. Lyon, MD, FACS, discusses future work building off the study, “Patient reported treatment burden and attitudes towards in-home intravesical therapy among patients with bladder cancer,” for which he served as the senior author. Lyon is an associate professor of urology at Mayo Clinic in Jacksonville, Florida.
Video Transcript:
On the basis of these findings, we've decided to move ahead with a phase 2 trial, specifically looking at the ability to deliver in-home intravesical therapies for patients with non-muscle invasive bladder cancer. The primary outcome will be feasibility of in-home treatments, with key secondary outcomes being patient preference for in-home vs in-clinic installations, as well as likelihood of recommending to other bladder cancer patients. Of course, we'll also be collecting safety data, patient-reported outcomes and quality of life data during the process.
This transcription has been edited for clarity.
Coding Q&A: Billing for female total urethrectomy with complete cystectomy
January 5th 2024"When we think about a typical procedure for performing a radical cystectomy for cancer with an ileal conduit, that would typically involve lymph node dissection, and therefore CPT 51595 would be best chosen to report that combined procedure," write Jonathan Rubenstein, MD, and Mark Painter.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
